Community Investing Ideas

Global Weekly Picks

CA$31.8
FV
98.5% undervalued intrinsic discount
544
users have viewed this narrative
13users have liked this narrative
7users have commented on this narrative
28users have followed this narrative
US$332.98
40.3% overvalued intrinsic discount
FineAnts's Fair Value
Revenue
40.05% p.a.
Profit Margin
14.1%
Future PE
39x
Price in 2027
US$440.49
US$86.27
1.2% undervalued intrinsic discount
Revenue
5% p.a.
Profit Margin
13%
Future PE
22x
Price in 2029
US$118.15
US$63
75.5% undervalued intrinsic discount
RockeTeller's Fair Value
Revenue
93.33% p.a.
Profit Margin
2.76%
Future PE
63.43x
Price in 2029
US$92.6
CA$5.4
97.2% undervalued intrinsic discount
RockeTeller's Fair Value
Profit Margin
9.5%
Future PE
N/A
Price in 2029
CA$0
US$75.23
12.7% undervalued intrinsic discount
Revenue
4% p.a.
Profit Margin
11.5%
Future PE
21x
Price in 2028
US$114.1
AU$0.26
55.8% undervalued intrinsic discount
LeoChivo's Fair Value
Revenue
0.69% p.a.
Profit Margin
7.3%
Future PE
12.02x
Price in 2029
AU$0.14
US$112.55
11.9% undervalued intrinsic discount
bucailei's Fair Value
Revenue
5.25% p.a.
Profit Margin
21.98%
Future PE
20.98x
Price in 2027
US$132.99
PPGN logo
PolyPeptide Group

Biotech longerterm bet

211011 Draupnir noch ein Anteil von rund 55,5% an Polypeptide. Der «Free Float» an der Börse SIX erhöht sich dadurch gleichzeitig von 40,0 auf rund 44,5%.Read more

View narrative
18
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CHF 33.1
23.6% undervalued intrinsic discount
PKU's Fair Value
Revenue
11.03% p.a.
Profit Margin
13.61%
Future PE
18.34x
Price in 2029
CHF 41.08
US$486.86
31.9% undervalued intrinsic discount
Revenue
9.81% p.a.
Profit Margin
4.05%
Future PE
25x
Price in 2026
US$537.61